A POSTMENOPAUSABAN ADOTT HORMONPOTLAS FELFOGHATO-E A CARDIOVASCULARIS BETEGSEGEK ES AZ OSTEOPOROSIS PRAEVENTIOJAKENT?

Translated title of the contribution: Can the postmenopausal hormone replacement therapy be considered as a prevention of cardiovascular diseases and osteoporosis?

M. Góth, J. Dancso

Research output: Contribution to journalArticle

Abstract

Epidemiologic evidence overwhelmingly supports the notion that estrogen-replacement therapy protects postmenopausal women from coronary artery disease. Still the appropriate treatment of these women with gonadal steroids remains controversial, since the benefits have been inferred from observation studies rather than demonstrated in prospective clinical trials. Preventive hormonal replacement therapy for postmenopausal women in general is unwarranted at present. The need for large-scale randomized trials of long term preventive hormone treatment is compelling. Almost all physicians believe that estrogen treatment can prevent osteoporosis, but on the basis of recent studies it can be concluded that estrogen therapy in the first decade after menopause cannot be expected to give enough protection against osteoporotic fractures decades later.

Original languageHungarian
Pages (from-to)216-222
Number of pages7
JournalOrvoskepzes
Volume70
Issue number4
Publication statusPublished - 1995

Fingerprint

Estrogen Replacement Therapy
Osteoporosis
Cardiovascular Diseases
Estrogens
Therapeutics
Osteoporotic Fractures
Menopause
Coronary Artery Disease
Steroids
Observation
Clinical Trials
Hormones
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A POSTMENOPAUSABAN ADOTT HORMONPOTLAS FELFOGHATO-E A CARDIOVASCULARIS BETEGSEGEK ES AZ OSTEOPOROSIS PRAEVENTIOJAKENT? / Góth, M.; Dancso, J.

In: Orvoskepzes, Vol. 70, No. 4, 1995, p. 216-222.

Research output: Contribution to journalArticle

@article{55e60768f0344edca9feaccb553cf5de,
title = "A POSTMENOPAUSABAN ADOTT HORMONPOTLAS FELFOGHATO-E A CARDIOVASCULARIS BETEGSEGEK ES AZ OSTEOPOROSIS PRAEVENTIOJAKENT?",
abstract = "Epidemiologic evidence overwhelmingly supports the notion that estrogen-replacement therapy protects postmenopausal women from coronary artery disease. Still the appropriate treatment of these women with gonadal steroids remains controversial, since the benefits have been inferred from observation studies rather than demonstrated in prospective clinical trials. Preventive hormonal replacement therapy for postmenopausal women in general is unwarranted at present. The need for large-scale randomized trials of long term preventive hormone treatment is compelling. Almost all physicians believe that estrogen treatment can prevent osteoporosis, but on the basis of recent studies it can be concluded that estrogen therapy in the first decade after menopause cannot be expected to give enough protection against osteoporotic fractures decades later.",
author = "M. G{\'o}th and J. Dancso",
year = "1995",
language = "Hungarian",
volume = "70",
pages = "216--222",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "4",

}

TY - JOUR

T1 - A POSTMENOPAUSABAN ADOTT HORMONPOTLAS FELFOGHATO-E A CARDIOVASCULARIS BETEGSEGEK ES AZ OSTEOPOROSIS PRAEVENTIOJAKENT?

AU - Góth, M.

AU - Dancso, J.

PY - 1995

Y1 - 1995

N2 - Epidemiologic evidence overwhelmingly supports the notion that estrogen-replacement therapy protects postmenopausal women from coronary artery disease. Still the appropriate treatment of these women with gonadal steroids remains controversial, since the benefits have been inferred from observation studies rather than demonstrated in prospective clinical trials. Preventive hormonal replacement therapy for postmenopausal women in general is unwarranted at present. The need for large-scale randomized trials of long term preventive hormone treatment is compelling. Almost all physicians believe that estrogen treatment can prevent osteoporosis, but on the basis of recent studies it can be concluded that estrogen therapy in the first decade after menopause cannot be expected to give enough protection against osteoporotic fractures decades later.

AB - Epidemiologic evidence overwhelmingly supports the notion that estrogen-replacement therapy protects postmenopausal women from coronary artery disease. Still the appropriate treatment of these women with gonadal steroids remains controversial, since the benefits have been inferred from observation studies rather than demonstrated in prospective clinical trials. Preventive hormonal replacement therapy for postmenopausal women in general is unwarranted at present. The need for large-scale randomized trials of long term preventive hormone treatment is compelling. Almost all physicians believe that estrogen treatment can prevent osteoporosis, but on the basis of recent studies it can be concluded that estrogen therapy in the first decade after menopause cannot be expected to give enough protection against osteoporotic fractures decades later.

UR - http://www.scopus.com/inward/record.url?scp=0028806118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028806118&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028806118

VL - 70

SP - 216

EP - 222

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 4

ER -